JNJ-69086420

N/A

Report date: 2025/09/24 16:01:09

Base Information

Drug NameJNJ-69086420

Drug Alias Name225Ac-DOTA-h11B6JNJ-69086420JNJ-6420

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agent +[4]

Mechanisms of ActionIonising radiation emittersAnti-KLK2

TargetsKallikrein 2

Therapy Area/IndicationsProstatic NeoplasmsAdenocarcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesJanssen Research & Development Llc

China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc

Inactive CompaniesN/A

Active IndicationsProstatic NeoplasmsAdenocarcinoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A